4
Press release: STADA acquires significant Consumer Healthcare portfolio from Orifarm for further growth acceleration
One document
more
- Language:
- Media:
- Period:
- Period:Total
Press Release: STADA strengthens CHC local hero brand portfolio by acquiring Locobase derma line in Nordics
STADA strengthens CHC local hero brand portfolio by acquiring Locobase derma line in Nordics - STADA strengthens Consumer Healthcare presence in Nordic countries by acquiring rights to Locobase® dermatology brand - Locobase® range of 17 products ...
One documentmorePress Release: Enzymatica and STADA sign partnership agreement for Germany and Austria
Press Release Enzymatica and STADA sign partnership agreement for Germany and Austria - New partnership agreement covers thelaunch and distribution of Enzymatica’s ColdZyme® oral-spray technology in Germany and Austria - Alliance combines Enzymatica’s clinically documented medical device with ...
One documentmore- 2
Press Release: STADA’s Strong Growth Journey Continues in 2025
One documentmore Press Release: STADA invests more than €85m in Saudi Arabia manufacturing hub
One documentmorePress Release: STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...
One documentmore
Press release: STADA’s Head of Communications Frank Staud additionally leads Global Government Affairs
One documentmorePress Release: Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
One documentmorePress Release: STADA welcomes Pedersen as General Counsel
One documentmore
Press Release: STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
3 DocumentsmorePress Release: STADA is in top 3% on pharma sustainability, Morningstar Sustainalytics assessment confirms
One documentmorePress Release: STADA Sponsors PingPongParkinson World Championship in Italy
One documentmore
Press release: STADA sees strong sales and earnings growth in H1
One documentmorePress release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
One documentmorePress Release : STADA brings in Henshaw from Biogen to head Specialty as Kim leads Western Europe
One documentmorePress Release: STADA’s continued, resilient growth leads to record earnings in Q1
One documentmore- 3
Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
One documentmore Press Release: STADA sets course for the future - experienced healthcare manager Andreas Fibig to become Chairman of the Board
One documentmore
Press Release: STADA welcomes Ingo Schachel as Head of Investor Relations
One documentmorePress Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
morePress release: STADA continues strong growth journey in the first half of 2024
One documentmore- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore
1